Twist Sale Purchase Of Stock vs Begin Period Cash Flow Analysis

TWST Stock

USD 48.12 0.18 0.38%

Twist Bioscience financial indicator trend analysis is much more than just breaking down Twist Bioscience Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Twist Bioscience Corp is a good investment. Please check the relationship between Twist Bioscience Sale Purchase Of Stock and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Twist Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Sale Purchase Of Stock vs Begin Period Cash Flow

Sale Purchase Of Stock vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Twist Bioscience Corp Sale Purchase Of Stock account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Twist Bioscience's Sale Purchase Of Stock and Begin Period Cash Flow is -0.58. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Twist Bioscience Corp, assuming nothing else is changed. The correlation between historical values of Twist Bioscience's Sale Purchase Of Stock and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Twist Bioscience Corp are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Sale Purchase Of Stock i.e., Twist Bioscience's Sale Purchase Of Stock and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.58

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Sale Purchase Of Stock

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Twist Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Twist Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Twist Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

At this time, Twist Bioscience's Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is expected to grow at the current pace this year, whereas Selling General Administrative is likely to drop slightly above 124.4 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.0M	29.3M	31.4M	33.0M
Interest Income	3.1M	14.4M	15.3M	16.1M

Depreciation And Amortization Interest Income

Twist Bioscience fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		-0.49	0.98	0.99	0.98	0.31	0.9	0.97	0.16	-0.87	-0.84	0.75	0.93	0.95	0.79	0.3	-0.89	0.97	0.97	0.8	0.96	0.41	-0.76	-0.54	0.9	0.99
Short Long Term Debt Total	-0.49		-0.4	-0.5	-0.64	-0.22	-0.58	-0.41	-0.4	0.36	0.45	-0.29	-0.39	-0.37	-0.32	-0.21	0.61	-0.54	-0.54	-0.32	-0.49	-0.62	0.93	1.0	-0.54	-0.45
Other Current Liab	0.98	-0.4		0.97	0.94	0.18	0.89	0.99	0.0	-0.81	-0.85	0.69	0.88	0.98	0.71	0.17	-0.82	0.91	0.94	0.85	0.94	0.38	-0.69	-0.45	0.89	0.97
Total Current Liabilities	0.99	-0.5	0.97		0.97	0.25	0.92	0.97	0.12	-0.84	-0.88	0.72	0.9	0.95	0.82	0.26	-0.91	0.94	0.97	0.84	0.97	0.4	-0.76	-0.54	0.92	0.98
Total Stockholder Equity	0.98	-0.64	0.94	0.97		0.32	0.9	0.94	0.23	-0.84	-0.82	0.73	0.9	0.91	0.76	0.31	-0.9	0.96	0.96	0.76	0.94	0.5	-0.86	-0.68	0.89	0.97
Other Liab	0.31	-0.22	0.18	0.25	0.32		0.15	0.11	0.79	-0.7	-0.08	0.4	0.61	0.08	0.5	1.0	-0.29	0.48	0.21	-0.08	0.25	-0.21	-0.23	-0.21	0.16	0.37
Net Tangible Assets	0.9	-0.58	0.89	0.92	0.9	0.15		0.9	0.0	-0.72	-0.98	0.44	0.79	0.88	0.73	0.14	-0.91	0.84	0.92	0.93	0.94	0.42	-0.84	-0.62	1.0	0.88
Property Plant And Equipment Net	0.97	-0.41	0.99	0.97	0.94	0.11	0.9		-0.08	-0.76	-0.87	0.66	0.84	1.0	0.72	0.1	-0.81	0.87	0.95	0.88	0.94	0.35	-0.7	-0.47	0.9	0.95
Current Deferred Revenue	0.16	-0.4	0.0	0.12	0.23	0.79	0.0	-0.08		-0.42	0.07	0.37	0.34	-0.13	0.4	0.82	-0.33	0.37	0.15	-0.33	0.14	0.22	-0.29	-0.39	0.01	0.19
Net Debt	-0.87	0.36	-0.81	-0.84	-0.84	-0.7	-0.72	-0.76	-0.42		0.65	-0.77	-0.99	-0.74	-0.83	-0.69	0.75	-0.92	-0.77	-0.58	-0.8	-0.11	0.59	0.39	-0.73	-0.91
Retained Earnings	-0.84	0.45	-0.85	-0.88	-0.82	-0.08	-0.98	-0.87	0.07	0.65		-0.36	-0.73	-0.86	-0.76	-0.07	0.89	-0.76	-0.89	-0.95	-0.93	-0.33	0.73	0.49	-0.98	-0.83
Accounts Payable	0.75	-0.29	0.69	0.72	0.73	0.4	0.44	0.66	0.37	-0.77	-0.36		0.77	0.66	0.67	0.42	-0.57	0.77	0.66	0.33	0.61	0.26	-0.43	-0.32	0.45	0.78
Cash	0.93	-0.39	0.88	0.9	0.9	0.61	0.79	0.84	0.34	-0.99	-0.73	0.77		0.82	0.84	0.6	-0.8	0.95	0.85	0.67	0.87	0.16	-0.64	-0.42	0.8	0.96
Non Current Assets Total	0.95	-0.37	0.98	0.95	0.91	0.08	0.88	1.0	-0.13	-0.74	-0.86	0.66	0.82		0.7	0.06	-0.78	0.83	0.93	0.88	0.92	0.3	-0.67	-0.42	0.88	0.94
Non Currrent Assets Other	0.79	-0.32	0.71	0.82	0.76	0.5	0.73	0.72	0.4	-0.83	-0.76	0.67	0.84	0.7		0.53	-0.85	0.79	0.82	0.61	0.85	0.13	-0.55	-0.35	0.76	0.84
Other Assets	0.3	-0.21	0.17	0.26	0.31	1.0	0.14	0.1	0.82	-0.69	-0.07	0.42	0.6	0.06	0.53		-0.3	0.47	0.21	-0.09	0.25	-0.2	-0.22	-0.2	0.15	0.37
Long Term Debt	-0.89	0.61	-0.82	-0.91	-0.9	-0.29	-0.91	-0.81	-0.33	0.75	0.89	-0.57	-0.8	-0.78	-0.85	-0.3		-0.9	-0.94	-0.74	-0.94	-0.57	0.82	0.65	-0.92	-0.88
Cash And Short Term Investments	0.97	-0.54	0.91	0.94	0.96	0.48	0.84	0.87	0.37	-0.92	-0.76	0.77	0.95	0.83	0.79	0.47	-0.9		0.92	0.67	0.9	0.46	-0.77	-0.58	0.84	0.97
Net Receivables	0.97	-0.54	0.94	0.97	0.96	0.21	0.92	0.95	0.15	-0.77	-0.89	0.66	0.85	0.93	0.82	0.21	-0.94	0.92		0.81	0.98	0.5	-0.79	-0.59	0.92	0.95
Good Will	0.8	-0.32	0.85	0.84	0.76	-0.08	0.93	0.88	-0.33	-0.58	-0.95	0.33	0.67	0.88	0.61	-0.09	-0.74	0.67	0.81		0.84	0.22	-0.63	-0.36	0.93	0.79
Common Stock Shares Outstanding	0.96	-0.49	0.94	0.97	0.94	0.25	0.94	0.94	0.14	-0.8	-0.93	0.61	0.87	0.92	0.85	0.25	-0.94	0.9	0.98	0.84		0.39	-0.76	-0.54	0.95	0.95
Short Term Investments	0.41	-0.62	0.38	0.4	0.5	-0.21	0.42	0.35	0.22	-0.11	-0.33	0.26	0.16	0.3	0.13	-0.2	-0.57	0.46	0.5	0.22	0.39		-0.61	-0.64	0.4	0.34
Long Term Debt Total	-0.76	0.93	-0.69	-0.76	-0.86	-0.23	-0.84	-0.7	-0.29	0.59	0.73	-0.43	-0.64	-0.67	-0.55	-0.22	0.82	-0.77	-0.79	-0.63	-0.76	-0.61		0.95	-0.81	-0.72
Non Current Liabilities Total	-0.54	1.0	-0.45	-0.54	-0.68	-0.21	-0.62	-0.47	-0.39	0.39	0.49	-0.32	-0.42	-0.42	-0.35	-0.2	0.65	-0.58	-0.59	-0.36	-0.54	-0.64	0.95		-0.58	-0.5
Capital Surpluse	0.9	-0.54	0.89	0.92	0.89	0.16	1.0	0.9	0.01	-0.73	-0.98	0.45	0.8	0.88	0.76	0.15	-0.92	0.84	0.92	0.93	0.95	0.4	-0.81	-0.58		0.89
Inventory	0.99	-0.45	0.97	0.98	0.97	0.37	0.88	0.95	0.19	-0.91	-0.83	0.78	0.96	0.94	0.84	0.37	-0.88	0.97	0.95	0.79	0.95	0.34	-0.72	-0.5	0.89

Click cells to compare fundamentals

Twist Bioscience Account Relationship Matchups

Twist Bioscience fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	398.9M	702.1M	961.4M	776.4M	614.3M	478.9M
Short Long Term Debt Total	36.0M	62.9M	94.9M	94.1M	85.0M	92.9M
Other Current Liab	14.3M	27.7M	53.5M	40.0M	34.9M	21.9M
Total Current Liabilities	36.0M	63.1M	90.7M	73.3M	71.0M	49.0M
Total Stockholder Equity	336.3M	580.8M	789.4M	623.4M	472.7M	310.8M
Other Liab	158K	351K	5.1M	60K	69K	65.6K
Net Tangible Assets	150.4M	334.8M	540.1M	789.4M	907.8M	953.2M
Property Plant And Equipment Net	59.2M	105.7M	214.4M	203.4M	161.3M	98.6M
Current Deferred Revenue	16.4M	18.8M	28.8M	3.5M	2.1M	2.0M
Net Debt	(57.7M)	(402.9M)	(283.8M)	(192.4M)	(141.3M)	(148.4M)
Retained Earnings	(458.5M)	(610.6M)	(828.4M)	(1.0B)	(1.2B)	(1.2B)
Accounts Payable	4.8M	14.9M	20.1M	14.1M	1.6M	1.5M
Cash	93.7M	465.8M	378.7M	286.5M	226.3M	200.2M
Non Current Assets Total	64.0M	155.6M	364.9M	352.1M	267.5M	157.2M
Non Currrent Assets Other	3.4M	9.2M	5.0M	8.5M	5.9M	5.3M
Other Assets	4.4M	3.4M	49.9M	(1K)	(1.2K)	(1.1K)
Cash And Short Term Investments	290.0M	477.9M	505.0M	336.4M	276.4M	271.7M
Net Receivables	26.4M	28.5M	40.3M	44.1M	34.9M	23.8M
Common Stock Shares Outstanding	39.2M	48.3M	53.9M	56.9M	58.0M	42.5M
Short Term Investments	196.3M	12.0M	126.3M	49.9M	50.1M	71.4M
Liabilities And Stockholders Equity	398.9M	702.1M	961.4M	776.4M	614.3M	478.9M
Non Current Liabilities Total	26.6M	58.2M	81.3M	79.6M	70.6M	86.5M
Capital Surpluse	470.4M	794.6M	1.2B	1.6B	1.9B	2.0B
Inventory	12.3M	31.8M	39.3M	32.1M	24.1M	19.1M
Other Current Assets	12.4M	16.6M	11.9M	11.7M	11.4M	8.9M
Other Stockholder Equity	794.6M	1.2B	1.6B	1.7B	1.7B	889.7M
Total Liab	62.6M	121.3M	172.0M	153.0M	141.6M	122.2M
Property Plant And Equipment Gross	59.2M	105.7M	214.4M	203.4M	237.0M	248.8M
Total Current Assets	334.9M	546.5M	596.5M	424.3M	346.8M	321.6M
Non Current Liabilities Other	25.2M	58.2M	60K	475K	407K	386.7K
Short Term Debt	16.2M	18.0M	13.6M	14.9M	29.6M	31.1M
Intangible Assets	307K	18.3M	59.7M	54.5M	14.5M	18.4M
Property Plant Equipment	20.8M	25.5M	44.1M	214.4M	246.5M	258.9M
Net Invested Capital	341.0M	1.6M	789.4M	623.4M	472.7M	284.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Twist Stock Analysis

When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC